


21

Please cancel claims 1, 3, 10-12, and 14-17 from the present application without disclaimer or prejudice.

Please amend claims 7, 8, 9, and 13 as follows:

Claim 7:

7. A compound of the formula B:



B

wherein:

X is O or H₂;

e is 0;

t is 1 to 4;

Sub
D10

822
Sub
D10

$R^{2'}$, $R^{3'}$, $R^{4'}$, and $R^{5'}$ are independently selected from: H; C_{1-8} alkyl, alkenyl, alkynyl, aryl, heterocycle, $-\text{CO}-\text{NR}^{6'}\text{R}^{7'}$ or $-\text{CO}-\text{OR}^{6'}$, unsubstituted or substituted with one or more of:

1) aryl or heterocycle, unsubstituted or substituted with:

- a. C_{1-4} alkyl,
- b. $(\text{CH}_2)_t\text{OR}^{6'}$,
- c. $(\text{CH}_2)_t\text{NR}^{6'}\text{R}^{7'}$,
- d. halogen,

2) C_{3-6} cycloalkyl,

3) $\text{OR}^{6'}$,

4) $\text{SR}^{6'}$, $\text{S}(\text{O})\text{R}^{6'}$, $\text{SO}_2\text{R}^{6'}$,

5) $-\text{NR}^{6'}\text{R}^{7'}$,

6) $-\text{NR}^{6'}-\text{CO}-\text{R}^{7'}$,

7) $-\text{NR}^{6'}-\text{CO}-\text{NR}^{7'}\text{R}^{8'}$,

8) $-\text{O}-\text{CO}-\text{NR}^{6'}\text{R}^{7'}$,

9) $-\text{O}-\text{CO}-\text{OR}^{6'}$,

10) $-\text{O}-\text{NR}^{6'}\text{R}^{7'}$,

11) $-\text{SO}_2\text{NR}^{6'}\text{R}^{7'}$,

12) $-\text{NR}^{6'}-\text{SO}_2-\text{R}^{7'}$,

13) $-\text{CO}-\text{R}^{6'}$, or

14) $-\text{CO}-\text{OR}^{6'}$;

and any two of $R^{2'}$, $R^{3'}$, $R^{4'}$, and $R^{5'}$ are optionally attached to the same carbon atom;

Y is aryl, heterocycle, unsubstituted or substituted with one or more of:

1) C_{1-4} alkyl, unsubstituted or substituted with:

22
Sub
b10

- a. C₁₋₄alkoxy,
- b. NR^{6'}R^{7'},
- c. C₃₋₆cycloalkyl,
- d. aryl or heterocycle,
- e. HO,

- 2) aryl or heterocycle,
- 3) halogen,
- 4) OR^{6'},
- 5) NR^{6'}R^{7'},
- 6) CN
- 7) NO₂, or
- 8) CF₃;

R^{6'}, R^{7'} and R^{8'} are independently selected from: H; C₁₋₄alkyl, C₃₋₆cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with:

- a) C₁₋₄alkoxy,
- b) aryl or heterocycle,
- c) halogen,
- d) HO,
- e) -CO-R^{9'},
- f) -SO₂R^{9'}, wherein

R^{6'} and R^{7'} may be joined in a ring, and

R^{7'} and R^{8'} may be joined in a ring;

R^{9'} is C₁₋₄alkyl or aralkyl;

a pharmaceutically acceptable salt thereof.

Claim 8:


8. The compound (2S)-2-(2-methoxyethyl)-1-((cis)-3-sulfanyl-pyrrolidin-2-ylmethyl)-4-naphthoyl-piperazine or a pharmaceutically acceptable salt thereof.

Claim 9:

9. A pharmaceutical composition which comprises a compound according to any one of claims 7 or 8 and a pharmaceutically acceptable carrier.

Claim 13:

13. A process for preparing compounds of the Formula B as defined in claim 7 which comprises deprotecting a compound of Formula VI:



wherein X⁸ represents the right hand side of the Formula B as defined in claim 7, Pr¹ is H or an amino protecting group, Pr² is H or a thio protecting group and any functional groups in X⁸ are optionally protected with the proviso that there is at least one protecting group and optionally, if desired, converting the product thus obtained into a pharmaceutically acceptable salt thereof.

Please add the following claims:

- 24
18. A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is a carcinoma of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid or skin.
19. A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is a hematopoietic tumor of lymphoid lineage selected from acute lymphocytic leukaemia, B-cell lymphoma and Burketts lymphoma.
20. A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is a hematopoietic tumor of myeloid lineage selected from acute or chronic myelogenous leukemias and promyelocytic leukaemia.
21. A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is a tumor of mesenchymal origin selected from fibrosarcoma and rhabdomyosarcoma.
22. A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-